In addition, the combined inhibition of the Hippo pathways has been shown to improve the response of tumours to treatment with KRAS G12C-specific inhibitors [88,89], suggesting significant therapeutic potential in cancer treatment and the integration of miRNAs that not only indirectly regulate KRAS, but also all those genes that regulate and are regulated by KRAS. This evidence concerns the gene KRAS and cancer.